United Therapeutics (UTHR) Free Cash Flow (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Free Cash Flow data on file, last reported at $363.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 5.85% year-over-year to $363.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 27.68% YoY), and the FY2025 full-year result was $1.4 billion, up 33.71% from the prior year.
• Free Cash Flow fell to $363.7 million in Q1 2026, from $577.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $577.5 million in Q4 2025 to a low of $38.7 million in Q2 2023.
• A 5-year average of $272.8 million and a median of $275.3 million in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 64.82% in 2023 and jumped 345.74% in 2024, its largest moves.
• Tracing UTHR's Free Cash Flow over 5 years: stood at $127.5 million in 2022, then soared by 31.06% to $167.1 million in 2023, then surged by 52.3% to $254.5 million in 2024, then soared by 126.92% to $577.5 million in 2025, then plunged by 37.02% to $363.7 million in 2026.
• Business Quant data shows UTHR's Free Cash Flow at $363.7 million in Q1 2026, $577.5 million in Q4 2025, and $280.7 million in Q3 2025.